Tech Talk - RareCyte (SITC 2026) - Sep 29, 2026 - Pres time: Nov 6, 2026; 06:45 PM - 07:00 PM; P1/2 | "We performed Orion multiplex immunofluorescence on 38 paired pre/on-treatment biopsies from 20 patients in a phase 1/2 trial of copanlisib plus nivolumab in microsatellite-stable colorectal cancer (NCT03711058). Together, these data establish the utility of Orion for tumor and immune biomarker discovery in biopsies obtained from immunotherapy trials. Jeremiah Wala, MD, PhD, Physician, Dana-Farber Cancer Institute"
IO biomarker • Colorectal Cancer • Oncology • Solid Tumor • CD8 • PD-L1
|